{"id":28482,"date":"2025-03-03T13:54:33","date_gmt":"2025-03-03T05:54:33","guid":{"rendered":"https:\/\/flcube.com\/?p=28482"},"modified":"2025-03-03T13:54:35","modified_gmt":"2025-03-03T05:54:35","slug":"grand-pharma-sells-telix-shares-for-aud-143m-to-fund-clinical-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28482","title":{"rendered":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs"},"content":{"rendered":"\n

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512<\/a>) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX<\/a>) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.<\/p>\n\n\n\n

Licensing Agreement and Investment<\/strong>
In November 2020, Grand Pharma licensed Telix\u2019s portfolio of molecularly-targeted radiation products for Greater China rights in a deal worth up to AUD 400 million (USD 249 million), including an equity investment of AUD 35 million (USD 21.8 million) in Telix.<\/p>\n\n\n\n

Telix’s Product Portfolio<\/strong>
Telix boasts TLX591-CDx, a radionuclide-drug conjugate (RDC) for the diagnosis of prostate cancer. The product is registered in the US, Australia, and Canada, among others, and has received positive opinions in the European Union. TLX591-CDx generated global sales of AUD 783 million (USD 487 million) in 2024, marking a 56% year-on-year increase.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in…<\/p>\n","protected":false},"author":1,"featured_media":28483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2403,16,683,1184,2402],"class_list":["post-28482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-asx-tlx","tag-cancer","tag-grand-pharmaceutical","tag-hkg-0512","tag-telix-pharmaceuticals"],"yoast_head":"\nGrand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28482\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs\" \/>\n<meta property=\"og:description\" content=\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28482\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T05:54:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-03T05:54:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs\",\"datePublished\":\"2025-03-03T05:54:33+00:00\",\"dateModified\":\"2025-03-03T05:54:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482\"},\"wordCount\":172,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0301-png.avif\",\"keywords\":[\"ASX: TLX\",\"Cancer\",\"Grand Pharmaceutical\",\"HKG: 0512\",\"Telix Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28482#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28482\",\"name\":\"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0301-png.avif\",\"datePublished\":\"2025-03-03T05:54:33+00:00\",\"dateModified\":\"2025-03-03T05:54:35+00:00\",\"description\":\"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28482\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0301-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/0301-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28482#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs - Insight, China's Pharmaceutical Industry","description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28482","og_locale":"en_US","og_type":"article","og_title":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs","og_description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.","og_url":"https:\/\/flcube.com\/?p=28482","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-03T05:54:33+00:00","article_modified_time":"2025-03-03T05:54:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28482#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28482"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs","datePublished":"2025-03-03T05:54:33+00:00","dateModified":"2025-03-03T05:54:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28482"},"wordCount":172,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=28482#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","keywords":["ASX: TLX","Cancer","Grand Pharmaceutical","HKG: 0512","Telix Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28482#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28482","url":"https:\/\/flcube.com\/?p=28482","name":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=28482#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=28482#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","datePublished":"2025-03-03T05:54:33+00:00","dateModified":"2025-03-03T05:54:35+00:00","description":"China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in its Australia partner Telix Pharmaceuticals Ltd (ASX: TLX) for AUD 143 million (USD 89 million). The proceeds will be used for clinical development targeting unmet clinical needs, including programs in collaboration with Telix. Grand Pharma has pledged not to sell the remaining 6 million shares of Telix within the next 12 months.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28482#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28482"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=28482#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","width":1080,"height":608,"caption":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28482#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/0301-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28482"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28482\/revisions"}],"predecessor-version":[{"id":28484,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28482\/revisions\/28484"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/28483"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}